02:00 AM EDT, 05/07/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows:

We adjust our target price to USD22 from USD20 and keep our EPADS estimates of EUR1.84 for 2025 and EUR2.06 for 2026. Q1 2025 results beat consensus with Care Enablement segment showing strong performance of 4.9% organic revenue growth and 2.4%-pt margin expansion, while Care Delivery segment saw 4.2% organic growth but was impacted by severe U.S. flu season and higher costs. Despite the Q1 beat, FME maintained its full-year guidance and expects U.S. same market treatment growth. We believe continued savings from the FME25 program will support margin improvement, though elevated excess mortality rates could challenge the company's goal of normalizing U.S. same market treatment growth to 2% by 2026. Considering the typical 6-to-8 weeks lag in mortality data, the full impact of the severe flu season, which peaked in February and March, might not be evident until May. Therefore, the treatment growth target could be at risk if the impact on mortality rates turns out to be worse than expected, in our view.